AAN 2024 Conference

Apr 26, 2024

Biohaven with BHV-7000 underscores unwavering commitment to neurology and to addressing unmet patient needs, by providing innovative therapeutic choices with improved tolerability for epilepsy patients.  BHV-7000, a selective activator of Kv7.2/7.3 potassium channels, presents a promising avenue, navigatin...

Apr 26, 2024

Fenebrutinib distinguishes itself from other BTK inhibitors through its unique reversible mechanism. It aims to treat relapsing and primary progressive MS.  Fenebrutinib treatment resulted in decreased new lesion activity and enhanced penetration into the cerebrospinal fluid (CSF) in multiple sclerosis (MS...

Apr 24, 2024

ULTOMIRIS (ravulizumab-cwvz) is the first and only long-acting C5 complement inhibitor that offers patients with aquaporin-4 (AQP4) antibody-positive (Ab+) neuromyelitis optica spectrum disorder (NMOSD) the potential to live relapse-free. In comparison to other therapeutic options, ravulizumab stands out as a s...

Apr 24, 2024

Sanofi is presently engaged in the exploration of Riliprubart (SAR445088), a monoclonal antibody designed to selectively target the serine protease C1s, in pursuit of its potential therapeutic application in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP). Riliprubart unveils compelling efficacy in CID...

Apr 24, 2024

ULTOMIRIS (ravulizumab-cwvz) is the first and only long-acting C5 complement inhibitor that offers patients with aquaporin-4 (AQP4) antibody-positive (Ab+) neuromyelitis optica spectrum disorder (NMOSD) the potential to live relapse-free. The remarkable reduction in relapse risk observed in the CHAMPION-NMOSD t...

Apr 24, 2024

Takeda and Ovid Therapeutics with soticlestat, a first-in-class cholesterol 24-hydroxylase inhibitor, holds promise for transformative therapy marking a milestone in advancing treatment options for individuals with refractory epilepsies associated with Dravet syndrome and Lennox-Gastaut syndrome.  Soticles...

Apr 24, 2024

Cenobamate, marketed as XCOPRI in the US and ONTOZRY in the EU, provides various dosage choices to improve treatment adherence and efficacy.  SK Life Science’s cenobamate via its multimodal approach, provides much-needed relief for patients with partial-onset seizures by reducing repetitive neuronal firing...

Apr 24, 2024

Athira Pharma presented a poster titled “Targeting Neurotrophic HGF Signaling for the Treatment of Neurodegenerative Disorders” at the recently, concluded American Academy of Neurology 2024 Annual Meeting, held in Denver, Colorado. It highlighted preclinical data supporting the development of Athira's pipeline of s...

Apr 24, 2024

Semaglutide provides a potential therapeutic avenue for aging-related neurodegenerative diseases, such as Alzheimer's disease through enhanced brain glucose metabolism. The comparable safety data presented by Novo Nordisk strengthens Semaglutide’s profile as a potential candidate in the early Alzheimer’s Diseas...

Apr 24, 2024

PRX012, a next-generation subcutaneous antibody, has the potential to eliminate treatment obstacles due to its unique pharmacological properties and improved binding profile compared to conventional amyloid-beta targeting medicines. PRX123, targeting the hallmarks of Alzheimer’s, Aβ plaque, and tau tangles, has...